| CTEPH (N = 92) |
---|---|
Age (years) | 59 ± 12 |
Female (%) | 63 (68%) |
Number of BPA sessions/patient | 2 (1, 3) |
Total BPA sessions | 210 |
Interval between BPA (days) | 80 (48, 131) |
Hemodynamics | |
 Heart rate | 81 ± 13 |
 Mean RAP (mmHg) | 7.4 ± 5.0 |
 Systolic PAP (mmHg) | 75.5 ± 25.6 |
 Diastolic PAP (mmHg) | 24.8 ± 9.0 |
 Mean PAP (mmHg) | 43.0 ± 13.6 |
 PVR (Wood Unit) | 10.3 ± 6.7 |
 Cardiac output (L/min) | 4.1 ± 1.8 |
 Cardiac index (L/min/m2) | 2.6 ± 1.1 |
 PASO2 (%) | 62.5 ± 10.2 |
 MVSO2 (%) | 93.9 ± 4.4 |
 NT-proBNP (pg/ml) | 541.1 (120.0, 1823.8) |
Exercise capacity | |
 WHO functional class (I/II/III/IV, %) | 7/45/36/4 (7.6/48.9/39.1/4.3) |
PAH targeted therapy (%) | 50 (54.3%) |
Riociguat | 28 (30.4) |
Macitentan | 11 (12.0) |
Treprostinil | 10 (10.9) |
Tadalafil | 8 (8.7) |
Sildenafil | 7 (7.6) |
Ambrisentan | 5 (5.4) |
Bosentan | 4 (4.3) |
Anticoagulation (%) | 92 (100%) |
Warfarin | 19 (20.7) |
Rivaroxaban | 64 (69.6) |
Dabigatran | 9 (9.8) |